Literature DB >> 19525450

Pretreatment with haloperidol reduces (123)I-FP-CIT binding to the dopamine transporter in the rat striatum: an in vivo imaging study with a dedicated small-animal SPECT camera.

Susanne Nikolaus1, Christina Antke, Konstantin Kley, Markus Beu, Andreas Wirrwar, Hans-Wilhelm Müller.   

Abstract

UNLABELLED: Synaptic dopamine is mainly regulated by presynaptic dopamine transporter (DAT) activity. We hypothesized that variations in synaptic dopamine are reflected by variations of DAT radioligand binding. The effect of haloperidol, which increases synaptic dopamine concentrations, was therefore assessed in the rat striatum using (123)I-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)-nortropane ((123)I-FP-CIT) as a DAT radioligand.
METHODS: Striatal (123)I-FP-CIT binding was measured in 24 rats under baseline conditions (no pretreatment) and at 1 h after injection of haloperidol or a vehicle (1 mg/kg) using a small-animal SPECT camera.
RESULTS: Baseline equilibrium ratios (V(3)'') were 1.32 +/- 0.24 (mean +/- SD). After the haloperidol injection, V(3)'' decreased to 0.99 +/- 0.38 (P(2-tailed) < 0.0001), corresponding to a mean reduction of DAT binding by 25%.
CONCLUSION: Our results are indicative of competition between the DAT ligand (123)I-FP-CIT and synaptic dopamine elevated by haloperidol, suggesting that the assessment of (123)I-FP-CIT binding may be suitable to study variations in synaptic dopamine in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19525450     DOI: 10.2967/jnumed.109.061952

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

1.  Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography.

Authors:  Hae-Won Shin; Jae Seung Kim; Minyoung Oh; Sooyeoun You; Young Jin Kim; Juyeon Kim; Mi-Jung Kim; Sun Ju Chung
Journal:  Neurol Sci       Date:  2014-09-18       Impact factor: 3.307

2.  Binding of [123I]iodobenzamide to the rat D2 receptor after challenge with various doses of methylphenidate: an in vivo imaging study with dedicated small animal SPECT.

Authors:  Susanne Nikolaus; Christina Antke; Markus Beu; Konstantin Kley; Andreas Wirrwar; Joseph P Huston; Hans-Wilhelm Müller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-26       Impact factor: 9.236

3.  (123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study.

Authors:  Françoise J Siepel; Arvid Rongve; Tirza C Buter; Mona K Beyer; Clive G Ballard; Jan Booij; Dag Aarsland
Journal:  BMJ Open       Date:  2013-04-08       Impact factor: 2.692

4.  Molecular SPECT Imaging: An Overview.

Authors:  Magdy M Khalil; Jordi L Tremoleda; Tamer B Bayomy; Willy Gsell
Journal:  Int J Mol Imaging       Date:  2011-04-05

5.  Proposed Motor Scoring System in a Porcine Model of Parkinson's Disease induced by Chronic Subcutaneous Injection of MPTP.

Authors:  Joon Ho Moon; Ji Ho Kim; Hyung-Jun Im; Dong Soo Lee; Eun Jung Park; Kilyoung Song; Hyun Ju Oh; Su Bin Hyun; Sang Chul Kang; Hyunil Kim; Hyo Eun Moon; Hyung Woo Park; Hong Jae Lee; Eun Ji Kim; Seokjoong Kim; Byeong Chun Lee; Sun Ha Paek
Journal:  Exp Neurobiol       Date:  2014-09-18       Impact factor: 3.261

6.  Combination of In Vivo [123I]FP-CIT SPECT and Microdialysis Reveals an Antipsychotic Drug Haloperidol-induced Synaptic Dopamine Availability in the Rat Midbrain and Striatum.

Authors:  So Hyeon Park; Yoo Sung Song; Byung Seok Moon; Byung Chul Lee; Hyun Soo Park; Sang Eun Kim
Journal:  Exp Neurobiol       Date:  2019-10-31       Impact factor: 3.261

7.  A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter.

Authors:  Davide Amato; Fabio Canneva; Paul Cumming; Simone Maschauer; Dominik Groos; Jana Katharina Dahlmanns; Teja W Grömer; Lisa Chiofalo; Marc Dahlmanns; Fang Zheng; Johannes Kornhuber; Olaf Prante; Christian Alzheimer; Stephan von Hörsten; Christian P Müller
Journal:  Mol Psychiatry       Date:  2018-07-23       Impact factor: 15.992

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.